XML 61 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-based compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Components of Stock-based Compensation Expense
The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):
Years ended December 31,
202420232022
RSUs$351 $309 $227 
Performance units133 121 132 
Stock options46 43 42 
Total stock-based compensation expense, pretax530 473 401 
Tax benefit from stock-based compensation expense(114)(102)(86)
Total stock-based compensation expense, net of tax$416 $371 $315 
Schedule of RSUs
The following table summarizes information regarding our RSUs:
Year ended December 31, 2024
Units
(in millions)
Weighted-average
grant date
fair value
Balance nonvested as of December 31, 2023
3.9 $246.43 
Granted1.5 $301.36 
Vested(1.6)$250.80 
Forfeited(0.3)$267.28 
Balance nonvested as of December 31, 2024
3.5 $265.07 
Schedule of Stock Option Assumptions
The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:
Years ended December 31,
202420232022
Closing price of our common stock on grant date$300.30$235.97 $230.92 
Expected volatility (average of implied and historical volatility)26.9 %23.3 %24.5 %
Expected life (in years)5.75.75.7
Risk-free interest rate4.4 %3.4 %2.8 %
Expected dividend yield3.2 %3.5 %3.3 %
Fair value of stock options granted$69.34$41.86 $42.43 
Schedule of Stock Options
The following table summarizes information regarding our stock options:
Year ended December 31, 2024
Options
(in millions)
Weighted-
average
exercise price
Weighted-
average
remaining
contractual
life (in years)
Aggregate
intrinsic
value
(in millions)
Balance unexercised as of December 31, 2023
5.9 $213.90 
Granted0.8 $300.32 
Exercised(0.6)$201.22 
Expired/forfeited(0.2)$248.94 
Balance unexercised as of December 31, 2024
5.9 $225.84 6.3$236 
Vested or expected to vest as of December 31, 2024
5.7 $224.34 6.2$234 
Exercisable as of December 31, 2024
3.1 $202.02 4.6$182 
Schedule of Weighted-Average Assumptions The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:
Years ended December 31,
202420232022
Closing price of our common stock on grant date$300.30 $235.97 $230.92 
Volatility22.1 %21.6 %28.1 %
Risk-free interest rate4.6 %3.7 %0.3 %
Fair value of units granted$321.61 $252.49 $247.48